Skip to main content
SpringerLink
Log in

Dermatofibrosarcoma Protuberans

  • Chapter
  • First Online:
Evidence-Based Procedural Dermatology

  • 1340 Accesses

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing sarcoma. DSFP has low metastatic potential but may be locally aggressive, exhibiting extensive subclinical extension and a high local recurrence rate. Treatment of disease centers on complete surgical resection with emphasis on negative histologic margins and maintaining good function and cosmesis. Treatment options include Mohs micrographic surgery (MMS), modified MMS, wide local excision (WLE), and WLE with circumferential and peripheral deep-margin pathologic assessment. MMS or modified MMS may allow lower recurrence rates than conventional WLE and may be considered first-line options. WLE with circumferential and peripheral deep-margin pathologic assessment may also enable lower recurrence rate with smaller margins. Postoperative adjuvant radiotherapy may be considered in unresectable disease. Imatinib mesylate may be used for unresectable, recurrent, and/or metastatic cases. Other targeted therapies may be beneficial. Treatment approach should take individual factors into account including patient comorbidities, tumor characteristics, and treatment availability.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kreicher KL, Kurlander DE, Gittleman HR, et al. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42:S24–31.

    CAS  PubMed  Google Scholar 

  2. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56(6):968–73.

    PubMed  Google Scholar 

  3. Rouhani P, Fletcher CD, Devesa SS, et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113(3):616–27.

    PubMed  Google Scholar 

  4. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711–20.

    CAS  PubMed  Google Scholar 

  5. Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol. 2006;20(10):1237–42.

    CAS  PubMed  Google Scholar 

  6. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014;3(5):1404–15.

    PubMed  PubMed Central  Google Scholar 

  7. Zlatnik MG, Dinh TV, Lucci JA 3rd, et al. Dermatofibrosarcoma protuberans of the vulva: report of two new cases and review of the literature. J Low Genit Tract Dis. 1999;3(2):135–8.

    CAS  PubMed  Google Scholar 

  8. Reha J, Katz SC. Dermatofibrosarcoma protuberans. Surg Clin North Am. 2016;96(5):1031–46.

    PubMed  Google Scholar 

  9. Kneebone RL, Melissas J, Mannell A. Dermatofibrosarcoma protuberans in black patients. S Afr Med J. 1984;66(24):919–21.

    CAS  PubMed  Google Scholar 

  10. McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases--five with metastasis. Ann Surg. 1967;166(5):803–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Ani AN, Attah EB, Ajayi OO. Dermatofibrosarcoma protruberans: analysis of eight cases in an African population. Am Surg. 1976;42(12):934–40.

    CAS  PubMed  Google Scholar 

  12. Kurlander DE, Martires KJ, Chen Y, et al. Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: a national study. J Am Acad Dermatol. 2013;68(5):790–6.

    PubMed  Google Scholar 

  13. Parlette LE, Smith CK, Germain LM, et al. Accelerated growth of dermatofibrosarcoma protuberans during pregnancy. J Am Acad Dermatol. 1999;41(5 Pt 1):778–83.

    CAS  PubMed  Google Scholar 

  14. Kreicher KL, Honda KS, Kurlander DE, et al. Hormone receptor expression in patients with dermatofibrosarcoma protuberans. J Am Acad Dermatol. 2016;75(6):1205–9.

    CAS  PubMed  Google Scholar 

  15. Buck DW, Kim JY, Alam M, et al. Multidisciplinary approach to the management of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 2012;67(5):861–6.

    PubMed  Google Scholar 

  16. Miller SJ, Alam M, Andersen JS, Berg D, National Comprehensive Cancer Network, et al. Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw. 2012;10(3):312–8.

    PubMed  Google Scholar 

  17. Saiag P, Grob JJ, Lebbe C, et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(17):2604–8.

    PubMed  Google Scholar 

  18. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100(5):1008–16.

    PubMed  Google Scholar 

  19. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol. 2010;17(8):2112–8.

    PubMed  Google Scholar 

  20. Lemm D, Mügge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135(5):653–65.

    PubMed  Google Scholar 

  21. Massey RA, Tok J, Strippoli BA, et al. A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans. Dermatol Surg. 1998;24(9):995–8.

    CAS  PubMed  Google Scholar 

  22. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg. 2012;38(4):537–51.

    CAS  PubMed  Google Scholar 

  23. Foroozan M, Sei JF, Amini M, et al. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9):1055–63.

    PubMed  Google Scholar 

  24. Criscito MC, Martires KJ, Stein JA. Prognostic factors, treatment, and survival in dermatofibrosarcoma protuberans. JAMA Dermatol. 2016;152(12):1365–71.

    PubMed  Google Scholar 

  25. Castle KO, Guadagnolo BA, Tsai CJ, et al. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):585–90.

    PubMed  Google Scholar 

  26. von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(6):758–86.

    Google Scholar 

  27. Akram J, Wooler G, Lock-Andersen J. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines. J Plast Surg Hand Surg. 2014;48(1):67–73.

    PubMed  Google Scholar 

  28. Heuvel ST, Suurmeijer A, Pras E, et al. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol. 2010;36(1):89–94.

    PubMed  Google Scholar 

  29. Khatri VP, Galante JM, Bold RJ, et al. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 2003;10(9):1118–22.

    PubMed  Google Scholar 

  30. Cai H, Wang Y, Wu J, et al. Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol. 2012;105(2):142–8.

    PubMed  Google Scholar 

  31. Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol. 2011;18(2):328–36.

    PubMed  Google Scholar 

  32. Bichakjian CK, Olencki T, Alam M, et al. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Cancer Netw. 2014;12(6):863–8.

    Google Scholar 

  33. Erdem O, Wyatt AJ, Lin E, et al. Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: prognostic significance of clinicopathologic variables. Am J Dermatopathol. 2012;34:24–34.

    PubMed  Google Scholar 

  34. Kim BJ, Kim H, Jin US, et al. Wide local excision for dermatofibrosarcoma protuberans: a single-center series of 90 patients. Biomed Res Int. 2015;2015:642549.

    PubMed  PubMed Central  Google Scholar 

  35. Woo KJ, Bang SI, Mun GH, et al. Long-term outcomes of surgical treatment for dermatofibrosarcoma protuberans according to width of gross resection margin. J Plast Reconstr Aesthet Surg. 2016;69(3):395–401.

    PubMed  Google Scholar 

  36. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37(4):600–13.

    CAS  PubMed  Google Scholar 

  37. Serra-Guillén C, Llombart B, Nagore E, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans allows tumour clearance with smaller margins and greater preservation of healthy tissue compared with conventional surgery: a study of 74 primary cases. Br J Dermatol. 2015;172(5):1303–7.

    PubMed  Google Scholar 

  38. Llombart B, Serra-Guillén C, Monteagudo C, et al. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol. 2013;30(1):13–28.

    PubMed  Google Scholar 

  39. Tan YG, Chia CS, Loh WL, et al. Single-institution review of managing dermatofibrosarcoma protuberans. ANZ J Surg. 2016;86(5):372–6.

    PubMed  Google Scholar 

  40. Loghdey MS, Varma S, Rajpara SM, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): a single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. J Plast Reconstr Aesthet Surg. 2014;67(10):1315–21.

    PubMed  Google Scholar 

  41. Meguerditchian AN, Wang J, Lema B, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol. 2010;33(3):300–3.

    PubMed  Google Scholar 

  42. Brewer JD, Roenigk RK, Otley CC. Wide local excision or Mohs micrographic surgery for primary dermatofibrosarcoma protuberans. Am J Clin Oncol. 2011;34(5):545–6.

    PubMed  Google Scholar 

  43. Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev. 2008;34(8):728–36.

    CAS  PubMed  Google Scholar 

  44. Barlow RJ, Mallipeddi R, Sheth N. Is Mohs micrographic surgery more effective than wide local excision for treatment of dermatofibrosarcoma protuberans in reducing risk of local recurrence? A critically appraised topic. Br J Dermatol. 2013;168(1):229–30.

    CAS  PubMed  Google Scholar 

  45. Matin RN, Acland KM, Williams HC. Is Mohs micrographic surgery more effective than wide local excision for treatment of dermatofibrosarcoma protuberans in reducing risk of local recurrence? A critically appraised topic. Br J Dermatol. 2012;167(1):6–9.

    CAS  PubMed  Google Scholar 

  46. Riggs K, McGuigan KL, Morrison WB, et al. Role of magnetic resonance imaging in perioperative assessment of dermatofibrosarcoma protuberans. Dermatol Surg. 2009;35(12):2036–41.

    CAS  PubMed  Google Scholar 

  47. Serra-Guillén C, Sanmartín O, Llombart B, et al. Correlation between preoperative magnetic resonance imaging and surgical margins with modified Mohs for dermatofibrosarcoma protuberans. Dermatol Surg. 2011;37(11):1638–45.

    PubMed  Google Scholar 

  48. Rutgers EJ, Kroon BB, Albus-Lutter CE, et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1992;18(3):241–8.

    CAS  PubMed  Google Scholar 

  49. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol. 2000;24(8):1125–30.

    CAS  PubMed  Google Scholar 

  50. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30(4):436–43.

    PubMed  Google Scholar 

  51. Liang CA, Jambusaria-Pahlajani A, Karia PS, et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71(4):781–6.

    PubMed  Google Scholar 

  52. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35(3 Pt 1):355–74; quiz 375–6.

    PubMed  Google Scholar 

  53. Barnes L, Coleman JA Jr, Johnson JT. Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol. 1984;110(6):398–404.

    CAS  PubMed  Google Scholar 

  54. Mark RJ, Bailet JW, Tran LM, et al. Dermatofibrosarcoma protuberans of the head and neck. A report of 16 cases. Arch Otolaryngol Head Neck Surg. 1993;119(8):891–6.

    CAS  PubMed  Google Scholar 

  55. Mullen JT. Dermatofibrosarcoma protuberans: wide local excision versus Mohs micrographic surgery. Surg Oncol Clin N Am. 2016;25(4):827–39.

    PubMed  Google Scholar 

  56. Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol. 2009;8(10):914–22.

    PubMed  Google Scholar 

  57. Yu W, Tsoukas MM, Chapman SM, et al. Surgical treatment for dermatofibrosarcoma protuberans: the Dartmouth experience and literature review. Ann Plast Surg. 2008;60(3):288–93.

    CAS  PubMed  Google Scholar 

  58. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol. 1996;14(8):2365–9.

    CAS  PubMed  Google Scholar 

  59. Marks LB, Suit HD, Rosenberg AE, et al. Dermatofibrosarcoma protuberans treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1989;17(2):379–84.

    CAS  PubMed  Google Scholar 

  60. Ballo MT, Zagars GK, Pisters P, et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys. 1998;40(4):823–7.

    CAS  PubMed  Google Scholar 

  61. Glazer ES, Prieto-Granada C, Zager JS. Current approaches to cutaneous sarcomas: dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. Curr Probl Cancer. 2015;39(4):248–57.

    PubMed  Google Scholar 

  62. Haas RL, Keus RB, Loftus BM, et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer. 1997;33(7):1055–60.

    CAS  PubMed  Google Scholar 

  63. Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol. 2000;57(2):175–81.

    CAS  PubMed  Google Scholar 

  64. Lindner NJ, Scarborough MT, Powell GJ, et al. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol. 1999;25(4):392–7.

    CAS  PubMed  Google Scholar 

  65. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100(6):623–6.

    CAS  PubMed  Google Scholar 

  66. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20(17):3586–91.

    CAS  PubMed  Google Scholar 

  67. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol. 2004;151(1):235–7.

    CAS  PubMed  Google Scholar 

  68. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866–73.

    CAS  PubMed  Google Scholar 

  69. Rutkowski P, Debiec-Rychter M, Nowecki Z, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol. 2011;25:264–70.

    CAS  PubMed  Google Scholar 

  70. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol. 2008;26(10):1757–9.

    PubMed  Google Scholar 

  71. Ugurel S, Mentzel T, Utikal J, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 2014;20(2):499–510.

    CAS  PubMed  Google Scholar 

  72. Kerob D, Porcher R, Ve’rola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res. 2010;16:3288–95.

    CAS  PubMed  Google Scholar 

  73. Odueyungbo M, Ratner D. Update on the use and treatment of targeted molecular inhibitors for locally advanced and metastatic non-melanoma skin cancers. Dermatol Surg. 2016;42(Suppl 1):S49–56.

    CAS  PubMed  Google Scholar 

  74. Kamar FG, Kairouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res. 2013;3(1):5.

    PubMed  PubMed Central  Google Scholar 

  75. Fu Y, Kang H, Zhao H, et al. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib. Int J Clin Exp Med. 2015;8(5):8288–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Alam M, Ibrahim O, Nodzenski M, et al. Adverse events associated with Mohs micrographic surgery: multicenter prospective cohort study of 20,821 cases at 23 centers. JAMA Dermatol. 2013;149(12):1378–85.

    PubMed  Google Scholar 

  77. Zbar RI. Identifying and managing those patients at risk for aborted Mohs micrographic surgery. Ann Plast Surg. 2012;68(1):67–71.

    CAS  PubMed  Google Scholar 

  78. Moore J, Isler M, Barry J, et al. Major wound complication risk factors following soft tissue sarcoma resection. Eur J Surg Oncol. 2014;40(12):1671–6.

    CAS  PubMed  Google Scholar 

  79. Chen YT, Tu WT, Lee WR, et al. The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(7):1107–14.

    PubMed  Google Scholar 

  80. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 2004;101(1):28–38.

    PubMed  Google Scholar 

  81. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30(3):341–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Private Practice, Houston, TX, USA

    Jennifer Hau

  2. University of California San Diego Health, Department of Dermatology, San Diego, CA, USA

    Shang I. Brian Jiang

Authors
  1. Jennifer Hau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shang I. Brian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shang I. Brian Jiang .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Northwestern University, Chicago, IL, USA

    Murad Alam

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hau, J., Jiang, S.I.B. (2019). Dermatofibrosarcoma Protuberans. In: Alam, M. (eds) Evidence-Based Procedural Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-02023-1_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02023-1_46

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02022-4

  • Online ISBN: 978-3-030-02023-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation